眼眶肉瘤AJCC第8版T和N分期与转移及生存的关联
该单中心回顾性队列研究纳入73例眼眶肉瘤患者,评估AJCC第8版TNM分期的预后价值。结果显示T和N分期与局部复发、淋巴结转移、远处转移及疾病死亡相关,T3及以上和N1病变风险更高,支持对高危患者加强监测。
要点
- T分期与所有疾病相关结局显著相关,T4风险最高。
- N1病变与远处转移和疾病死亡风险显著增加相关。
- T3及以上和/或N1患者应考虑严格区域淋巴结和全身转移监测。
核心结论
- 眼眶肉瘤患者初诊时AJCC第8版T和N分期与转移和生存相关。
- 研究结果支持对T3及以上和/或N1病变患者考虑严格监测区域淋巴结和全身转移。
研究设计与样本
- 单中心回顾性队列研究,纳入2003年3月1日至2018年6月30日连续治疗的73例眼眶肉瘤患者。
- 数据分析时间为2018年11月1日至12月31日。
主要发现
- 73例患者中男性43例(59%),中位年龄21岁(范围0-77岁)。
- 常见组织学类型为横纹肌肉瘤35例(48%)、孤立性纤维瘤/血管外皮细胞瘤10例(14%)、尤文肉瘤8例(11%)。
- 最常见TNM分期为T2N0M0 26例(36%)和T4N0M0 24例(33%)。
- T分期与局部复发、淋巴结转移、远处转移和疾病死亡风险相关。
- T3及以上、N1病变、肿瘤大小>3cm、RMS患者年龄<1岁或≥10岁与远处转移和/或疾病死亡风险升高相关。
关键数值与推荐
- 远处转移风险:T2 vs T4的HR为0.29(95%CI 0.08-1.07),P=0.04。
临床怎么用
- 对眼眶肉瘤患者初诊时进行AJCC第8版TNM分期评估。
- 对T3及以上和/或N1病变患者考虑严格监测区域淋巴结和全身转移。
局限性
- 单中心回顾性研究,样本量73例,可能存在选择偏倚。
- 未报告外部验证或多中心数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: No previous studies to date have validated the American Joint Committee on Cancer (AJCC) 8th edition of the TNM classification for orbital sarcoma. OBJECTIVES: To determine the prognostic performance of the most recent TNM classification for orbital sarcoma and to identify other prognostic factors for local recurrence, lymph node metastasis, distant metastasis, and death due to disease. DESIGN, SETTING, AND PARTICIPANTS: This single-center retrospective cohort study included 73 consecutive patients treated for orbital sarcoma from March 1, 2003, through June 30, 2018. Data were analyzed from November 1 to December 31, 2018. MAIN OUTCOMES AND MEASURES: T and N categories at presentation and disease-related outcomes, including local recurrence, lymph node metastasis, distant metastasis (DM), and death due to disease (DD). RESULTS: The 73 participants included 43 men (59%), and the median age was 21 (range, 0-77) years. The common histologic types were rhabdomyosarcoma (RMS) (35 [48%]), solitary fibrous tumor/hemangiopericytoma (10 [14%]), and Ewing sarcoma (8 [11%]). The most common TNM designations were T2 N0 M0 (26 [36%]) and T4 N0 M0 (24 [33%]). T category was associated with the risk of all disease-related outcomes, including local recurrence (hazard ratio [HR] for T2 vs T4, 0.22 [95% CI, 0.06-0.81]; HR for T3 vs T4, 0.59 [95% CI, 0.13-2.65]; P = .03), lymph node metastasis by the last follow-up (T1, 1 [14%]; T2, 0; T3, 0; T4, 12 [35%]; P = .001), DM (HR for T2 vs T4, 0.29 [95% CI, 0.08-1.07]; P = .04), and DD (HR of T2 vs T4, 0.16 [95% CI, 0.04-0.73]; HR of T3 vs T4, 0.30 [95% CI, 0.04-2.34]; P = .02). Higher risk of DM and higher risk of DD were associated with disease category of at least T3 (HR for DM, 3.24 [95% CI, 0.89-11.72; P = .06]; HR for DD, 6.32 [95% CI, 1.43-27.95; P = .005]), N1 disease (HR for DM, 13.33 [95% CI, 4.07-43.65; P < .001]; HR for DD, 7.07 [95% CI, 2.45-20.44; P < .001]), tumor size larger than 3 cm (HR for DM, 2.72 [95% CI, 0.92-8.05; P = .06]; HR for DD, 5.79 [95% CI, 1.85-18.14; P < .001]), and age of patient with RMS younger than 1 year or 10 years or older (HR for DM, 6.85 [95% CI, 0.83-56.53; P = .04]; HR for DD, 7.03 [95% CI, 0.85-57.83; P = .04]). Higher risk of local recurrence was associated with disease category of at least T3 (HR for<T3 vs≥T3, 0.20 [95% CI, 0.06-0.71]; P < .01) and tumor size greater than 3 cm (HR for ≤3 cm vs >3 cm, 0.27 [95% CI, 0.09-0.77]; P = .009). Higher risk of lymph node metastasis was associated with disease category of at least T3 (odds ratio [OR], 13.33 [95% CI, 1.77-602.30]; P = .004), alveolar RMS (OR, 9.98 [95% CI, 2.13-51.55]; P = .001), and age of patient with RMS younger than 1 year or 10 years or older (OR, 9.20 [95% CI, 1.01-458.29] P = .03). CONCLUSIONS AND RELEVANCE: In patients with orbital sarcoma, T and N categories at presentation (defined by the AJCC 8th edition classification) correlate with metastasis and survival. These findings appear to support consideration of strict surveillance testing for regional nodal and systemic metastases in patients with orbital sarcoma with disease category of at least T3 and/or N1 disease.
引用
- Sa HS, Rubin ML, Ning J, et al. Association of T and N Categories of the American Joint Commission on Cancer, 8th Edition, With Metastasis and Survival in Patients With Orbital Sarcoma. JAMA Ophthalmol. 2020. PMID: 32105303. doi:10.1001/jamaophthalmol.2020.0039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。